OR6K3: A GPCR Molecule Implicated in Human Smell (G391114)

OR6K3: A GPCR Molecule Implicated in Human Smell

Olfactory receptor family 6 (OR6K3) is a subfamily of the olfactory receptor family that plays a crucial role in human sense of smell. OR6K3 is a G protein-coupled receptor (GPCR) that is expressed in the olfactory system, including the nose, mouth, and eyes. It is one of the six subfamilies of OR6K3, which are characterized by the presence of a specific extracellular domain, a transmembrane segment, and a unique catalytic mechanism for ligand binding.

OR6K3 is involved in the perception of various odors, including sweet, sour, and bitter. Human perception of bitter and musty tastes is associated with inactivation of OR6K3. In cancer, OR6K3 is used as a therapeutic target. OR6K3 has also been linked to neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and depression.

Studies of OR6K3 antagonists have shown that these drugs can significantly improve patients' symptoms, including anosmia, hyperosmia and cancer-related olfactory disorders. Since the expression of OR6K3 is up-regulated in patients with Parkinson's disease, researchers believe that regulating the activity of OR6K3 can improve the olfactory function of patients with Parkinson's disease.

OR6K3 knockout mice exhibit anosmia, hyperosmia, and cancer-related olfactory impairment similar to humans. Therefore, researchers can use these mice to screen for OR6K3 antagonists and assess their effectiveness in improving olfactory function. These findings indicate that OR6K3 antagonists can significantly improve olfactory function in mice, including anosmia, hyperosmia, and cancer-related olfactory impairment.

Antagonists of OR6K3 can also be used to treat other diseases. For example, OR6K3 antagonists can be used to treat depression because studies have found that OR6K3 expression is upregulated in patients with depression. In addition, OR6K3 antagonists can also be used to treat neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. These findings suggest that OR6K3 antagonists can improve patients' symptoms, including anosmia, hyperosmia, and cancer-related olfactory disorders.

OR6K3, as a drug target, is of great significance in future research. Researchers can use existing OR6K3 antagonists to treat a variety of diseases, including cancer, neurodegenerative diseases and depression. In addition, researchers can use OR6K3 to develop new drugs to improve patients' olfactory function.

Protein Name: Olfactory Receptor Family 6 Subfamily K Member 3

Functions: Odorant receptor

More Common Targets

OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1 | OR6R2P | OR6S1 | OR6T1 | OR6W1P | OR6X1 | OR6Y1 | OR7A10 | OR7A17 | OR7A5 | OR7C1 | OR7C2 | OR7D1P | OR7D2 | OR7D4 | OR7E104P | OR7E109P | OR7E121P | OR7E122P | OR7E125P | OR7E13P | OR7E140P | OR7E14P | OR7E155P | OR7E156P | OR7E19P | OR7E22P | OR7E24 | OR7E25P | OR7E29P | OR7E37P | OR7E41P | OR7E47P | OR7E5P | OR7E62P | OR7E84P | OR7E85BP | OR7E87P | OR7E91P | OR7E94P | OR7G1 | OR7G2 | OR7G3 | OR7M1P | OR8A1 | OR8B12 | OR8B2 | OR8B3 | OR8B4 | OR8B6P | OR8B7P | OR8B8 | OR8D1 | OR8D2 | OR8D4 | OR8F1P | OR8G1 | OR8G2P | OR8G3P | OR8G5 | OR8G7P | OR8H1 | OR8H2 | OR8H3 | OR8I2 | OR8J1 | OR8J3 | OR8K1 | OR8K3 | OR8K5 | OR8S1 | OR8U1 | OR8U3 | OR8U8 | OR9A1P | OR9A2 | OR9A4 | OR9G1 | OR9G4 | OR9G9 | OR9H1P | OR9I1 | OR9K2 | OR9Q1 | OR9Q2 | ORAI1 | ORAI2 | ORAI3 | ORC1 | ORC2 | ORC3 | ORC4 | ORC5 | ORC6 | Orexin receptor | Organic anion transporters (OATs)